SURMOUNT-4: Weight regain despite continuing lifestyle and diet modifications

Not surprising at all. Stopping cholesterol drugs while keeping lifestyle changes still lets numbers drift upward. The placebo participants probably noticed the return of hunger signals and the small justifications for extra snacks.

Hard to picture going through 36 weeks of reduced appetite and then being switched to nothing. I doubt the entire placebo group kept the lifestyle changes going.

The claim that people stayed on the lifestyle plan has to be false. How can anyone gain weight while truly in a 500-calorie deficit plus regular cardio?

A comparable trial is running with another medication that gives the drug for 80 weeks then randomizes to placebo or continued treatment for 26 weeks. I expect the same pattern of regain.

Every diet I tried ended with the weight returning. This result does not shock me. My own weight curve over 75 weeks on the medication has stayed down, so I plan to keep using it long term.

This paper is a later analysis of the original trial data looking at how heart-related measures changed with different amounts of regain after stopping treatment. The main trial already showed regain once the medication ended. The new finding is that the heart-risk improvements did not disappear evenly; about one-fifth of the placebo group regained less than a quarter of the earlier loss.

The graph shows clearly what occurs when treatment stops and supports staying on these medications for maintenance. Even those who stopped still kept some of the weight reduction and risk improvement. Earlier research already showed that losing just 5 to 10 percent brings measurable benefits.

People with diabetes were left out of this analysis. Randomizing successful participants to placebo afterward feels harsh. The data make a strong case that continued treatment is needed to hold the gains, but it probably will not persuade insurers to keep covering the cost once someone is no longer classified as obese.

Other medications after stopping the main treatment have been tested at universities and appear to help some people hold the loss. Companies that make the primary drugs have little reason to study those switches, but independent research exists. Anyone who may lose coverage or cannot continue can look into those options.

In the analysis, 9 percent regained more than all the weight they had lost after stopping, while 4 percent kept losing.

Participants went straight from a full treatment dose to zero. That sudden drop is not how dosing normally starts or stops. The data only prove that stopping abruptly leads to regain; they do not prove everyone must regain if the medication is phased out or replaced. The design creates headlines but leaves the body swinging between extremes.

Those older alternatives did not work well for me before. Another medication that increases glucose excretion looks more useful even though it raises urination frequency.

After stopping cold turkey, food tasted much more appealing by the end of week three and weight started climbing noticeably in week four. Avoiding highly rewarding foods almost completely may be one workable approach during that window.

I finished a trial arm with no taper. The last dose was followed by one final blood draw six weeks later. Basic nutrition advice was given but nothing beyond “keep doing what you were doing.” The doctor predicted almost certain full regain. The following weeks were rough until I could resume treatment. I had also restarted regular gym time during the study and found that eating above maintenance helped muscle gain quickly.

The body may not simply flip back to prior production levels after months or years of suppression. Similar long-term hormone treatments can leave lasting changes. The person experiences the drop relative to the new higher baseline, which feels like a deficit even after the drug itself has cleared. That is physical dependence, separate from addiction.

Early placebo-controlled trials were required to prove safety and effectiveness before the medication existed outside studies. Later placebo arms raise harder questions, yet clear data on heart disease and death require those comparisons. The knowledge gained can still benefit future patients, including possibly the participants themselves once treatment becomes available.

Hello darkness my old friend… food noise.

I have accepted that I will stay on this type of medication indefinitely, not only for weight but for the other benefits. I finally feel in control of food rather than the other way around, and I am not giving that up after decades of fighting it.

I spend almost no time worrying whether I will stay on one of these medications for life. The answer is yes, just like statins. That frees up mental energy for other things.

I am not upset about likely lifelong use. The previous choices were staying heavy or staying obsessed with food and probably staying heavy anyway. Having the option of a weekly shot is a big improvement.

One related medication might help with maintenance after stopping or at lower doses because it affects the digestive tract differently. It could give one company an edge until newer options arrive, though the gut slowing may not suit everyone.